Although Angelman syndrome has provided a vivid illustration of how the loss of maternal UBE3A can derail these processes, the emerging recognition of UBE3A’s broader contributions across neurodevelopmental and neurodegenerative conditions calls for a deeper investigation of its glial and cross-cell activities. This evidence concerns the gene UBE3A and Angelman syndrome.